These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 19366576)

  • 41. Efficacy of vaccination for bluetongue virus serotype 8 performed shortly before challenge and implications for animal trade.
    Spedicato M; Lorusso A; Salini R; Gennaro AD; Leone A; Teodori L; Casaccia C; Portanti O; Calistri P; Giovannini A; Savini G
    Prev Vet Med; 2017 Jan; 136():49-55. PubMed ID: 28010907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiation between field and vaccine strain of bluetongue virus serotype 16.
    Monaco F; Cammà C; Serini S; Savini G
    Vet Microbiol; 2006 Aug; 116(1-3):45-52. PubMed ID: 16713688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.
    Top S; Foucras G; Deplanche M; Rives G; Calvalido J; Comtet L; Bertagnoli S; Meyer G
    Vaccine; 2012 Feb; 30(9):1609-16. PubMed ID: 22244980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of different vaccination schemes used in sheep combining inactivated bluetongue vaccines against serotypes 4 and 8.
    Hilke J; Strobel H; Woelke S; Stoeter M; Voigt K; Grimm L; Meilwes J; Punsmann T; Blaha I; Salditt A; Rohn K; Bastian M; Ganter M
    Vaccine; 2019 Sep; 37(39):5844-5853. PubMed ID: 31431410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.
    van Gennip RG; van de Water SG; Maris-Veldhuis M; van Rijn PA
    PLoS One; 2012; 7(9):e44619. PubMed ID: 23049753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection of Spanish Ibex (Capra pyrenaica) against Bluetongue virus serotypes 1 and 8 in a subclinical experimental infection.
    Lorca-Oró C; Pujols J; García-Bocanegra I; Mentaberre G; Granados JE; Solanes D; Fandos P; Galindo I; Domingo M; Lavín S; López-Olvera JR
    PLoS One; 2012; 7(5):e36380. PubMed ID: 22666321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transplacental transmission of BTV-8 in sheep: BTV viraemia, antibody responses and vaccine efficacy in lambs infected in utero.
    van der Sluijs MT; Schroer-Joosten DP; Fid-Fourkour A; Smit M; Vrijenhoek MP; Moulin V; de Smit AJ; Moormann RJ
    Vaccine; 2013 Aug; 31(36):3726-31. PubMed ID: 23746457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of a quadrivalent modified-live bluetongue virus vaccine in wildlife species.
    McConnell S; Morrill JC; Livingston CW
    Prog Clin Biol Res; 1985; 178():631-8. PubMed ID: 2989912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bluetongue virus serotype 26: infection kinetics and pathogenesis in Dorset Poll sheep.
    Batten CA; Henstock MR; Bin-Tarif A; Steedman HM; Waddington S; Edwards L; Oura CA
    Vet Microbiol; 2012 May; 157(1-2):119-24. PubMed ID: 22177889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bluetongue vaccines: the past, present and future.
    Bhanuprakash V; Indrani BK; Hosamani M; Balamurugan V; Singh RK
    Expert Rev Vaccines; 2009 Feb; 8(2):191-204. PubMed ID: 19196199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of an inactivated bluetongue serotype 8 vaccine on semen quality in rams.
    Leemans J; Raes M; Saegerman C; Sustronck B; Makoschey B; Kirschvink N
    Vet J; 2012 Aug; 193(2):567-9. PubMed ID: 22365834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
    Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
    Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4.
    Veronesi E; Darpel KE; Hamblin C; Carpenter S; Takamatsu HH; Anthony SJ; Elliott H; Mertens PP; Mellor PS
    Vaccine; 2010 Feb; 28(5):1397-403. PubMed ID: 19895921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serial inoculation of sheep with two bluetongue virus types.
    Jeggo MH; Wardley RC; Brownlie J; Corteyn AH
    Res Vet Sci; 1986 May; 40(3):386-92. PubMed ID: 3016851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental bluetongue infections in gnotobiotic lambs and kids.
    Livingston CW; McConnell S; Cummings G; Gauer BB
    Am J Vet Res; 1983 Jan; 44(1):129-31. PubMed ID: 6297338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Comtet L; Lövgren Bengtsson K; Pringle J; Zientara S; Valarcher JF
    Clin Vaccine Immunol; 2013 Aug; 20(8):1115-22. PubMed ID: 23720365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.